The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses

NCT01337557

Allergic Conjunctivitis

UNKNOWN PHASE4

A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft

NCT01339507

Allergic Conjunctivitis

COMPLETED

Ocular Responses to Short and Long-term Lens Wear

NCT00722891

Ametropia

COMPLETED NA

Patient Satisfaction and Tear Osmolarity With the Use of Blink Tears, Blink Gel Tears and Systane Balance

NCT01589640

Dry Eye

UNKNOWN

Performance of Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution in a New Packaging Configuration

NCT00659815

Comfort

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single-center, randomized, parallel group, placebo-controlled study to evaluate the effect of BEPREVE compared to a placebo eye drop on the measurement of tear film osmolarity and tear film lipid layer in patients with allergic conjunctivitis.

Subjects will be screened for this study on day one of dosing with the test article. Subjects who sign the informed consent form and who meet all inclusion/exclusion criteria will be eligible for participation in this study. They will be assigned sequentially, according to a computer generated randomization list, in a ratio of 1:1 to receive either BEPREVE™ (bepotastine besilate ophthalmic solution) 1.5% or REFRESH TEARS® Lubricant Eye Drops (1:1). Subjects will instill one drop of test article either BEPREVE™ or REFRESH TEARS® into the study eyes twice daily for a maximum of 60 days. Subjects will be seen for evaluation on Days 0, 28±3, and 56±3 following randomization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Conjunctivitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Refresh Tears® eye drops

Must add drops twice a day every day during trial enrollment.

Group Type PLACEBO_COMPARATOR

Bepreve 1.5% Ophthalmic Solution

Intervention Type DRUG

Bepreve® 1.5% solution

Must add drops twice a day every day while enrolled in trial.

Group Type EXPERIMENTAL

Refresh Tears 0.5% Lubricant Eye Drops

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Refresh Tears 0.5% Lubricant Eye Drops

Intervention Type DRUG

Bepreve 1.5% Ophthalmic Solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Are male or female at least 18 years of age who are diagnosed with allergic conjunctivitis.
2. Have documented positive skin prick puncture test to at least one (1) seasonal allergen (e.g., grasses, trees, weeds, or other allergens) within two (2) years of Visit 1.
3. Agree not to have any other ocular drops in study eyes within 2 days prior to the initiation of dosing with the test article or throughout the duration of the study.
4. Have a Best Corrected Visual Acuity of 20/200 or better in either eye.
5. Are willing/able to follow instructions from the study investigator and his/her staff.
6. Be willing/able to return for all required study visits, to follow instructions from the study investigator and his/her staff.
7. Are able to self-administer test article (or have a caregiver available to instill all doses of test article).
8. Have signed informed consent approved by Institutional Review Board or Independent Ethics Committee.

Exclusion Criteria

1. Have known hypersensitivity to either BEPREVE™ or REFRESH TEARS® or to any component of the test article (including "procedural" medications such as anesthetic and/or fluorescein drops, dilating drops, etc.).
2. Have active corneal pathology noted in the study eye at the screening visit. Active corneal pathology is defined as corneal pathology that is non-stable, or greater than mild, or will compromise assessment of the safety or efficacy of treatment.
3. Have used topical, ocular, inhaled or systemic steroids within 14 days prior to screening.
4. Have a history of abuse of alcohol/drugs within six months prior to the screening visit.
5. Are pregnant or nursing/lactating.
6. Have participated in any other study of an investigational drug or device within 30 days prior to randomization.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes